The global assisted reproductive technology (ART) market features moderately fragmented competitive landscape, finds Transparency Market Research (TMR). Several top players are widening their portfolio and focusing on geographic expansion to consolidate their shares in the global market. Some of the prominent players operating in the market are Merck & Company, Inc., Nikon Corporation, Esco Micro Pte. Ltd., Planer PLC, Laboratoire CCD, Nidacon International AB, Hamilton Thorne, Inc., Vitrolife AB, Irvine Scientific, and CooperSurgical, Inc. Merck, a globally prominent pharmaceutical company, accounted for the leading market share in 2016 on account of its robust portfolio and substantial clout it held in key regional markets.
The global assisted reproductive technology stood at US$22,100.0 million in 2016 and is projected to reach a revenue worth of US$37,789.6 million by 2025 end. During the assessment period of 2017–2025, the global market is anticipated to expand at a CAGR of 6.3%.
The broad procedures in assisted reproductive technology comprise frozen non donor, frozen donor, fresh non donor, embryo banking, and fresh donor. Of all these, the use of fresh non-donor cycle is anticipated to emerge as the dominant one. Their widespread demand can be attributed to the marked preference of parents to have children from their own genes.
On the geographical front, Asia Pacific is expected to contribute leading revenue to the global market over the assessment period. The growth will be fueled by substantially rising demand from emerging economies to address several infertility problem among the population. Meanwhile, North America is a potentially lucrative regional market attributed to the rising uptake of ART services in the U.S.
Request a PDF Brochure For Assisted Reproductive Technology Market @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=29234
Effectiveness of ART Procedures in Treating Various Infertility Problems bolsters Demand
The rising incidence of infertility across the globe, along with the substantially rising disposable incomes of couples in various parts of the world, is a key factor underpinning the evolution of the assisted reproductive technology market. The growing awareness about ART services among the population globally to effectively improve maternal and infant outcomes is a notable trend bolstering the demand.
The growth of the market receives a marked momentum from the rising government funding of in vitro fertilization (IVF) technology in numerous developing and developed nations. The rising initiative by governments of several countries to regulate the provision of ART procedures to enhance their safety and effectiveness augurs well for their demand. Furthermore, continuous government efforts in developing countries to improve the healthcare infrastructure for fertility treatments are fueling the growth of the assisted reproductive technology market.
Substantial Advances in ART Procedures unlock Promising Prospects
The global market has greatly benefitted from the constant evolution of ART protocols, notably in intrauterine insemination (IUI) and IVF. Rapid advances being made in various procedures related to ART have improved the live birth rates among couples, especially those with unexplained fertility problems. In this regard, substantial progress made in pre-implantation genetic diagnosis (PGD) in recent years have enabled physicians and fertility specialists to improve the maternal and child outcomes of assisted reproductive technologies. Furthermore, rapid advancement in genetic techniques is expanding our knowledge in assessing pre-treatment characteristics, thereby proving vital to the success rate of ART procedures.
However, the market is still to realize its full potential in less developed economies or even in few emerging economies which are plagued by the lack of adequate healthcare infrastructure supporting assisted reproductive technology treatments. The rising prevalence of reproductive problems, along with the growing social acceptance of ART procedures, in emerging economies is catalyzing the market growth.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Assisted Reproductive Technology Market – (Technology – In Vitro Fertilization (Intra-cytoplasmic Sperm Injection (ICSI) and Preimplantation Genetic Diagnosis (PGD)), Artificial Insemination (Intrauterine Insemination (IUI) and Intracervical Insemination (ICI)), and Surrogacy; Procedure – Frozen Donor, Frozen Non Donor, Fresh Donor, Fresh Non Donor, and Embryo Banking; End User – Fertility Clinics and Hospitals) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.
The global assisted reproductive technology market is segmented based on:
- In Vitro Fertilization
- Intra-cytoplasmic Sperm Injection (ICSI)
- Preimplantation Genetic Diagnosis (PGD)
- Artificial Insemination
- Intrauterine Insemination (IUI)
- Intracervical Insemination (ICI)
- Frozen Donor
- Frozen Non Donor
- Fresh Donor
- Fresh Non Donor
- Embryo Banking
- Fertility Clinics
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC countries
- South Africa
- Rest of Middle East & Africa